INTRODUCTION

Plants produce a wide variety of secondary compounds that provide them characteristic pigment, odour and flavour characteristics and may also give them antimicrobial properties. Traditional plant derived medicines have been used in most parts of the world for a variety of therapeutic purposes, including fighting microbial disease. Indeed, the ability of plant extracts to block the growth of pathogenic bacteria has become a focus of substantial recent study. Much of the research into traditional medicinal plant use has focused on Asian, African and South American plants. The first Australians had well-developed medicinal systems and understood the therapeutic properties of a wide variety of Australian plants and how to use them effectively. Despite this, relatively few studies have rigorously examined the antibacterial activity of Australian native plants, although there has recently been a substantial increase in interest in this field.

The development of antibiotic agents to treat Pseudomonas aeruginosa infections is particularly important as this pathogen may extensively colonise infected tissue and can aggregate to produce enduring biofilms that are particularly difficult to eradicate. P. aeruginosa is an opportunistic, nosocomial pathogen which most frequently infects the airways, urinary tract, burns and wounds, particularly in immunocompromised people. The bacterium is a frequent coloniser of medical devices (e.g. catheters) and is readily spread via contaminated equipment. Cystic fibrosis patients are particularly predisposed to P. aeruginosa infections of the lungs and if left untreated, they may be fatal. Furthermore, P. aeruginosa is recognised as a bacterial trigger of multiple sclerosis in genetically susceptible individuals. Of further concern, P. aeruginosa is resistant to most frontline antibiotic therapies due to its multiple efflux pumps which are encoded by mexAB, mexXY etc. resistance genes. The bacterium cell envelope also has low permeability to antibiotics, including a chloroquine resistant strain. Extracts prepared using young branches of Xanthophyllum neglectum develop into elliptical shaped fruit (~9 x 4cm). Whilst there is a lack of studies reporting the ethnobotanical uses, bioactivity and phytochemistry of X. neglectum, several studies have examined the ethnobotany, bioactivities and phytochemistry of other Xanthophyllum spp. Xanthophyllum excelsum root decoctions are used by the Lundayeh people of Sabah, Malaysia to treat gastritis. Extracts prepared using young branches of Xanthophyllum neglectum are used in Borneo to treat cold sweats and trembling. A further study reported good anti-Plasmodium falciparum activity (IC_{50} <2µg/mL) for the Philippine species Xanthophyllum flavescens Roxb. against two P. falciparum strains, including a chloroquine resistant strain. Interestingly, that study also reported the X. flavescens extracts to be non-toxic in both Artemia nauplii and human cell line cytotoxicity assays. The phytochemistry of Xanthophyllum spp. is relatively unreported, studies have reported that some species contain relatively levels of tannins, including gallic acid (Figure 1b) and protocatechuic acid (Figure 1c). Despite the earlier studies into the use and therapeutic properties of other Xanthophyllum spp., we were unable to find similar reports into the therapeutic properties of X. neglectum. Our study was undertaken to screen of X. neglectum leaf extracts for growth inhibitory properties against the important human bacterial pathogen, P. aeruginosa.

Xanthophyllum fragrans C.T. White Leaf Extracts Inhibit the Growth of Pseudomonas aeruginosa

Lindiwe Mpala, Getmore Chikowe, Ian Edwin Cock

1School of Environment and Science, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland, AUSTRALIA.
2Environmental Futures Research Institute, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland, AUSTRALIA.

ABSTRACT

Introduction: Xanthophyllum fragrans C.T. White is a rainforest tree that is native to north-eastern regions of Australia. X. fragrans leaf extracts were examined for the ability to inhibit the growth of Pseudomonas aeruginosa. Methods: The antimicrobial activity of a methanolic X. fragrans leaf extracts were investigated by disc diffusion and growth time course assays against P. aeruginosa. The growth inhibitory activity was further quantified by MIC determination. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: The methanolic X. fragrans leaf extract was a potent inhibitor of P. aeruginosa growth (MICs of 430 and 1687µg/mL against the reference and clinical strains respectively). The aqueous X. fragrans leaf extract was a moderate inhibitor of P. aeruginosa growth (MIC of 1250µg/mL against the reference and clinical bacterial strains respectively). The antibacterial activities of the methanolic X. fragrans leaf extracts were further investigated using growth time course assays that showed significant growth inhibition in cultures of P. aeruginosa within 1 h of exposure. All extracts were determined to be non-toxic in the Artemia franciscana nauplii bioassay, indicating their safety for use in preventing diseases caused by these pathogens. Conclusion: The lack of toxicity of the X. fragrans leaf extracts and their growth inhibitory bioactivity against P. aeruginosa indicates their potential in the development of new therapies targeting this bacterium.

Key words: Polygalaceae, Fragrant boxwood, Australian plant, Traditional medicine, Antibacterial, Cystic fibrosis, Multiple sclerosis.

Correspondence: Dr. Ian Edwin Cock

1School of Environment and Science, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, AUSTRALIA.
2Environmental Futures Research Institute, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, AUSTRALIA.
Phone no: +61 7 37357637
E-mail: I.Cock@griffith.edu.au
DOI: 10.5530/pj.2019.3.22
activity using 5mm sterilised filter paper discs. Discs were infused with 10µL of the plant extract, allowed to dry and placed onto the inoculated plates. The plates were allowed to stand at 4°C for 2 h before incubation at 30°C for 24 h. The diameters of the zones of inhibition (ZOIs) were measured to the closest whole millimetre. Each assay was performed three times in triplicate (n=9). Mean values (± SEM) are reported in this study. Standard discs of ampicillin (10µg) and chloramphenicol (10µg) were obtained from Oxoid, Australia and were used as positive controls to compare antibacterial activity. Filter discs infused with 10µL of distilled water were used as a negative control.

Minimum inhibitory concentration (MIC) determination
The minimum inhibitory concentration (MIC) of each extract was determined as previously described.21,22 Briefly, the methanolic X. fragrans leaf extract was diluted in deionised water and tested across a range of concentrations. Discs were infused with 10µL of the test dilutions, allowed to dry and placed onto the inoculated plates. The assay was completed as outlined above and graphs of the zone of inhibition versus concentration were plotted for each extract. Linear regression was used to determine the MIC values of each extract.

Bacterial growth time course assay
Bacterial growth time course studies were performed as previously described.22 Briefly, 3mL of P. aeruginosa (ATCC39324) in nutrient broth was added to 27mL nutrient broth containing 3mL of 10mg/mL of each individual extract to give a final concentration of 1000µg/mL in the assay. The tubes were incubated at 30°C with gentle shaking. The optical density was measured hourly at 550nm for a 6 h incubation period. Control tubes were incubated under the same conditions but without the extract. All assays were performed in triplicate.

Toxicity screening
Reference toxin for toxicity screening
Potassium dichromate (K₂Cr₂O₇) (AR grade, Chem-Supply, Australia) was prepared as a 4mg/mL solution in distilled water and was serially diluted in artificial seawater for use in the Artemia franciscana nauplii bioassay.

Artemia franciscana nauplii toxicity screening
Toxicity was tested using an adapted Artemia franciscana nauplii lethality assay.24,25 Briefly, 400µL of seawater containing approximately 44 (mean 44.3, n= 125, SD 11.6) A. franciscana nauplii were added to wells of a 48 well plate and immediately used for bioassay. A volume of 400µL of diluted plant extracts or the reference toxin were transferred to the wells and incubated at 25 ± 1°C under artificial light (1000 Lux). A 400µL seawater negative control was run in triplicate for each plate. All treatments were performed in at least triplicate. The wells were checked at regular intervals and the number of dead counted. The nauplii were considered dead if no movement of the appendages was detected within 10 sec. After 24 h, all nauplii were sacrificed and counted to determine the total % mortality per well. The LC₅₀ with 95% confidence limits for each treatment was determined using probit analysis.

Statistical analysis
Data are expressed as the mean ± SEM of at least three independent experiments. One-way ANOVA was used to calculate statistical significance between control and treated groups with a P value < 0.01 considered to be statistically significant.
To determine the growth inhibitory activity of the *X. fragrans* leaf extracts against the two *P. aeruginosa* strains, aliquots (10µL) of each extract were screened in the disc diffusion assay. The *X. fragrans* leaf extract inhibited the growth of both the reference and clinical isolate strains of *P. aeruginosa* (Figure 2). The reference strain was substantially more sensitive to the *X. fragrans* extracts and to the control antibiotics than was the clinically isolated strain. The methanolic extract was a particularly good inhibitor of the reference strain, with a zone of inhibition of 10.3 ± 0.6mm. The potency of this extract compared well with that of the positive control antibiotics ampicillin and chloramphenicol (ZOIs of 10.2 ± 0.6mm and 13.3 ± 0.3mm respectively). The inhibition of this extract is particularly noteworthy as each of the control antibiotics was tested at high doses (10µg/disc). The methanolic extract also was a particularly potent inhibitor of the growth of the reference *P. aeruginosa* strain, with an MIC value of 430µg/mL (~4µg infused into the disc). This extract was also a strong inhibitor of the clinical isolate *P. aeruginosa* strain (MIC 975µg/mL). As *P. aeruginosa* can trigger multiple sclerosis in genetically susceptible people, this extract may be useful for preventing this disease (and other diseases caused by this bacterium). This extract may also be particularly beneficial in individuals with cystic fibrosis, to limit pulmonary infections, thereby increasing their quality of life and life expectancy. Generally, substantially higher MIC values were determined for the aqueous extract (1500-2500 µg/mL; equivalent to ~15-25µg infused into the disc). Whilst substantially less potent than the methanolic extract, these MIC values are still indicative of moderate inhibitory activity. Therefore, the aqueous extract may still be useful in the development of new anti-*P. aeruginosa* therapies.
Table 2: Minimum inhibitory concentrations (µg/mL) of the *X. fragrans* leaf extracts against the *P. aeruginosa* strains and LC₅₀ values (µg/mL) against *Artemia* nauplii.

<table>
<thead>
<tr>
<th>Bacteria/toxicity</th>
<th>Exposure time (h)</th>
<th>M</th>
<th>W</th>
<th>CND</th>
<th>CND</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>P. aeruginosa</em> (ATCC39324)</td>
<td>24</td>
<td>430</td>
<td>975</td>
<td>CND</td>
<td>CND</td>
</tr>
<tr>
<td><em>P. aeruginosa</em> (clinical strain)</td>
<td>24</td>
<td>1687</td>
<td>2446</td>
<td>CND</td>
<td>CND</td>
</tr>
<tr>
<td>LC₅₀ (µg/mL)</td>
<td>48</td>
<td>72</td>
<td>CND</td>
<td>CND</td>
<td>CND</td>
</tr>
</tbody>
</table>

Numbers indicate the mean MIC or LC₅₀ values of three independent experiments in triplicate (n=9). CND indicates that an LC₅₀ could not be determined as the mortality did not exceed 50% at any concentration tested.

**Bacterial growth time course assay**

The antibacterial activity of the *X. fragrans* leaf extracts was further investigated against the reference (Figure 3a) and clinical strains (Figure 3b) of the bacterium by bacterial growth time course assays in the presence and absence of the methanolic and aqueous *X. fragrans* extracts. The starting concentration of the extracts used in these assays was 1000µg/mL. The *X. fragrans* methanolic and aqueous extracts significantly inhibited the growth of both *P. aeruginosa* strains within 1 h of exposure, indicating a rapid antimicrobial action. The absorbance of both *P. aeruginosa* strain cultures in the presence of the aqueous extract (and thus the bacterial growth) had returned to similar levels to that of the untreated control by the end of the 6h incubation period. This may indicate that the aqueous *X. fragrans* extract has bacteriostatic effects against *P. aeruginosa*. Similarly, the growth of the clinical *P. aeruginosa* isolate had returned to similar levels as the untreated control by the end of the 6h incubation (Figure 3b). In contrast, the A₅₉₀ of the reference *P. aeruginosa* culture in the presence of the methanolic extract was substantially lower than the untreated control following 6 h exposure (Figure 3a). However, the absorbance was increasing towards the control value at 6 h, indicating that this extract was still have bacteriostatic effects against the reference *P. aeruginosa* strain at the concentration tested.

**Quantification of toxicity**

The toxicity of the *X. fragrans* extracts was initially tested undiluted in the *Artemia franciscana* nauplii bioassay (Figure 4). The mortality in the presence of both extracts was not significantly different to that of the untreated control at 24 h and thus both extracts were non-toxic. Extracts with 24 h LC₅₀ values >1000µg/mL have previously been defined as non-toxic.²⁶ In contrast, the potassium dichromate positive control induced substantial mortality within 4 h (results not shown), with 100% mortality induction seen by 24 h. By 48 h, the mortality induction had also increased in the presence of both *X. fragrans* extracts and this increased further by 72 h exposure. However, the % mortality was still <50% at all times tested. Thus, both *X. fragrans* extracts were deemed to be non-toxic.

**DISCUSSION**

Plant derived remedies are increasingly sought after in the treatment of a myriad of diseases and disorders, due both to their perception of greater safety than synthetic drugs and the failure of some current drug regimens to effectively treat disease. New therapeutics are required particularly urgently for the treatment of *P. aeruginosa* infections due to the serious nature of some of the illnesses caused by this bacterium, as well as the resistance of this bacterium to most current antibiotics. *P. aeruginosa* infections are a major cause of lung infections in people...
with cystic fibrosis. Cystic fibrosis sufferers have mutations in the gene encoding CF-transmembrane conductance regulator protein, resulting in ineffective electrolyte secretion function and viscous mucus. As mucociliary clearance is a major mechanism of lung defense against bacterial infections, individuals with cystic fibrosis are ineffective at clearing these bacteria, resulting in chronic lung infections (most frequently \( \text{Pseudomonas aeruginosa} \) infections). If not effectively treated, these infections may be fatal. Indeed, \( \text{Pseudomonas aeruginosa} \) lung infections are the major cause of morbidity and mortality in people with cystic fibrosis.\(^{3,4} \) \( \text{Pseudomonas aeruginosa} \) (and \( \text{Acinetobacter} \) spp.) can also trigger multiple sclerosis in genetically susceptible people.\(^{5,6} \) Thus, limiting \( \text{Acinetobacter} \) spp. and \( \text{Pseudomonas aeruginosa} \) infections in the GI and/or respiratory tracts before they interact with the immune system may prevent the downstream inflammatory phase of the disease.

Of further concern, \( \text{Pseudomonas aeruginosa} \) has multiple efflux pumps encoded by mexAB, mexXY etc resistance genes,\(^{7} \) making it resistant to most antibiotics in clinical usage. Furthermore, the \( \text{Pseudomonas aeruginosa} \) cell envelope has low permeability to many clinically used antibiotics, further limiting their efficacy. Some \( \text{Pseudomonas aeruginosa} \) strains have also accumulated genes for the production of antibiotic degrading/inactivating enzymes such as extended-spectrum \( \beta \)-lactamases, AmpC cephalosporinases, carbapenemases, aminoglycoside-modifying enzymes etc. Combined, these resistance mechanisms make \( \text{Pseudomonas aeruginosa} \) infections particularly difficult to treat and new, effective antibiotics are urgently required. Probing traditional medicines and natural plant resources offers an alternate means of fighting bacterial diseases and may provide future therapies to treat \( \text{Pseudomonas aeruginosa} \) infections.

Our study reports on the growth inhibitory properties of a methanolic and aqueous \( \text{X. fragrans} \) leaf extracts against two strains of \( \text{Pseudomonas aeruginosa} \) and on their toxicity. The methanolic extract was a particularly potent inhibitor of \( \text{Pseudomonas aeruginosa} \) growth (MICs of 430 and 1687\( \mu \)g/mL against the reference and clinical strains respectively). The aqueous \( \text{X. fragrans} \) leaf extract was also a moderate inhibitor of \( \text{Pseudomonas aeruginosa} \) growth (MICs approximately 1000 and 2500\( \mu \)g/mL against the reference and clinical bacterial strains). Therefore, these extracts may be useful in treating lung infections in cystic fibrosis sufferers. Furthermore, as \( \text{Pseudomonas aeruginosa} \) may trigger multiple sclerosis in genetically susceptible individuals,\(^{7,8} \) these extracts may also be useful in the prevention and treatment of that autoimmune disease.

Whilst a detailed investigation of the phytochemistry of the \( \text{X. fragrans} \) leaf extracts was beyond the scope of our study, qualitative screening studies were used to determine the classes of compounds present. Notably, the extract contained relatively high levels of total phenolics, flavonoids and tannins. It is likely that these and other phytochemical classes may contribute to the growth inhibitory properties of the \( \text{X. fragrans} \) extracts. Many studies have reported potent antibacterial activities for a wide variety of compounds of these classes.\(^{9,10} \) Tannins have potent, broad spectrum growth inhibitory activity against a variety of bacterial species.\(^{11,12} \) Galloyltannins have particularly well reported inhibitory properties.\(^{13,14} \) They function via multiple mechanisms including interacting with both cell surface proteins\(^{15,16} \) and through interactions with intracellular enzymes.\(^{17,18} \) Ellagitannins also interact with cellular proteins and induce disruptions in bacterial cell walls.\(^{19,20} \) Similarly, multiple studies have reported potent antibacterial activity for a variety of flavonoids against a broad panel of pathogenic bacteria.\(^{21,22} \) Indeed, that report highlighted the growth inhibition of a methicillin resistant \( \text{Staphylococcus aureus} \) (MRSA) by luteolin. It is therefore likely that the tannin and flavonoid components of the \( \text{X. fragrans} \) leaf extracts may contribute to the bacterial growth inhibitory activity reported in our study. However, it is likely that other phytochemical components of these extracts may also contribute to the efficacy of these extracts. Further phytochemical evaluation studies and bioactivity driven isolation of the mechanism of active components is required to further evaluate the mechanism of bacterial growth inhibition.

The findings reported here also demonstrate that the \( \text{X. fragrans} \) leaf extracts were non-toxic towards \( \text{Artemia franciscana} \) nauplii, with \( \text{LC}_{50} \) values substantially \( >1000\mu \)g/mL. Extracts with \( \text{LC}_{50} \) values \( >1000\mu \)g/mL towards \( \text{Artemia} \) nauplii are defined as being non-toxic.\(^{23} \) Whilst our preliminary toxicity studies indicate that these extracts may be safe for therapeutic use, studies using human cell lines are required to further evaluate the safety of these extracts. Furthermore, whilst these studies have demonstrated the potential of the \( \text{X. fragrans} \) leaf extracts in the development of future antibiotic chemotherapeutics to treat \( \text{Pseudomonas aeruginosa} \) infections such as those associated with cystic fibrosis and the induction of multiple sclerosis in genetically susceptible people (as well as other diseases caused by \( \text{Pseudomonas aeruginosa} \) infections), more work is required to isolate the inhibitory components and determine the mechanism of inhibition. Whilst these studies have demonstrated the potential of the methanolic \( \text{X. fragrans} \) leaf extract in the development of future antibiotic chemotherapeutics, more work is required to isolate the inhibitory components and determine the mechanism of inhibition.

CONCLUSION

The results of this study demonstrate the potential of the \( \text{X. fragrans} \) leaf extracts as inhibitors of the growth of \( \text{X. fragrans} \). Furthermore, their lack of toxicity indicates that they are safe therapeutically. Further studies aimed at the purification and identification of bioactive components are required to examine the mechanisms of action of these agents.

ACKNOWLEDGEMENT

The authors are grateful to Philip Cameron for identifying and providing the plant material used in this study. We are also grateful to Michelle Mendell and Jane Gifkins for the gift of the clinical isolate bacterial strain. Financial support for this work was provided by the Environmental Futures Research Institute and the School of Natural Sciences, Griffith University, Australia.

CONFLICT OF INTEREST

The authors report no conflicts of interest.

ABBREVIATIONS

\( \text{DMSO}: \) Dimethyl sulfoxide; \( \text{LC}_{50} \): The concentration required to achieve 50\% mortality; \( \text{MIC} \): Minimum inhibitory concentration; \( \text{ZOI} \): Zone of inhibition.

REFERENCES

**PICTORIAL ABSTRACT**

**Xanthophyllum fragrans** leaf extracts were tested for the ability to inhibit the growth of clinical and reference *Pseudomonas aeruginosa* strains. The inhibitory activity was quantified by MIC determination. Bacterial growth time course assay were used to further evaluate the nature of the growth inhibition.

**TOXICITY** was studied in the *Artemia nauplii* bioassay.

---

**SUMMARY**

- *Xanthophyllum fragrans* leaf extracts were tested for the ability to inhibit the growth of clinical and reference *Pseudomonas aeruginosa* strains.

- The inhibitory activity was quantified by MIC determination.

- Bacterial growth time course assay were used to further evaluate the nature of the growth inhibition.

- Toxicity was studied in the *Artemia nauplii* bioassay.

---

**ABOUT AUTHORS**

Ms Lindiwe Mpala completed at BSc at Griffith University in life sciences. Following graduation, she undertook a research project in Dr Ian Cook’s laboratory in the School of Natural Sciences at Griffith University. The project examined the growth inhibitory properties of a variety of Australian native plants against an extensive panel of bacterial pathogens.

Ms Getmore Chikowe completed at BSc at Griffith University in life sciences. Following graduation, she undertook a research project in Dr Ian Cook’s laboratory in the School of Natural Sciences at Griffith University. The project examined the growth inhibitory properties of a variety of Australian native plants against an extensive panel of bacterial pathogens.